Department of Gastroenterology (Asan Liver Center), University of Ulsan College of Medicine, Seoul, Korea.
Liver Transpl. 2013 Mar;19(3):336-45. doi: 10.1002/lt.23584.
We retrospectively investigated the prognostic value of hepatocyte nuclear factor 1 (HNF1) proteins in 159 liver transplant patients with hepatocellular carcinoma (HCC), including 36 (22.6%) exceeding the Milan criteria. The expression of alpha-fetoprotein (AFP), HNF1α, and HNF1β was examined with immunohistochemistry on duplicate tissue microarray slides containing HCC tumor explants. The times to recurrence and cancer death were analyzed with a Cox regression model and were compared according to the expression of markers of interest. We compared risk predictions with area under the receiver operator curves (AUROCs) and C statistics. AFP, HNF1α, and HNF1β were positive in 22.6%, 46.5%, and 61.0% of the tumor immunoprofiles, respectively. Although several variables were associated with the times to recurrence and cancer death in univariate Cox analyses, only AFP expression for the time to recurrence and the Milan criteria and HNF1β expression for the times to recurrence and cancer death remained significant after multivariate adjustments. The expression of HNF1β (but not HNF1α) was related to a serum AFP level ≥ 200 ng/mL, microvascular invasion, and AFP expression (P < 0.05 for all). A subgroup analysis showed that in the group meeting the Milan criteria, recurrence and cancer death rates at 10 years in the HNF1β-negative patients were approximately one-tenth of those in the HNF1β-positive patients, but the difference was not significant in the group exceeding the Milan criteria. The addition of HNF1β expression to the Milan criteria increased the C statistics and AUROCs for both recurrence and mortality (P < 0.05 for all). In conclusion, the immunohistological detection of HNF1β predicts recurrence and HCC-specific death after transplantation and provides an additive benefit in comparison with the Milan selection criteria on their own.
我们回顾性研究了核因子 1 (HNF1)蛋白在 159 例肝癌(HCC)肝移植患者中的预后价值,其中 36 例(22.6%)超过米兰标准。采用免疫组织化学法在包含 HCC 肿瘤标本的组织微阵列载玻片上检测 alpha-胎蛋白(AFP)、HNF1α 和 HNF1β 的表达。采用 Cox 回归模型分析复发和癌症死亡时间,并根据感兴趣标志物的表达进行比较。我们比较了风险预测与接受者操作特征曲线(AUROCs)和 C 统计量的关系。肿瘤免疫组化图谱中 AFP、HNF1α 和 HNF1β 的阳性率分别为 22.6%、46.5%和 61.0%。尽管单变量 Cox 分析中多个变量与复发和癌症死亡时间相关,但多变量调整后,只有 AFP 表达与复发时间以及米兰标准和 HNF1β 表达与复发和癌症死亡时间相关仍然显著。HNF1β(而非 HNF1α)的表达与血清 AFP 水平≥200ng/ml、微血管侵犯和 AFP 表达相关(P<0.05)。亚组分析显示,在符合米兰标准的患者中,HNF1β 阴性患者的 10 年复发和癌症死亡发生率约为 HNF1β 阳性患者的十分之一,但在超过米兰标准的患者中差异无统计学意义。将 HNF1β 表达加入米兰标准后,复发和死亡率的 C 统计量和 AUROCs 均增加(P<0.05)。总之,HNF1β 的免疫组织化学检测可预测移植后复发和 HCC 特异性死亡,并与米兰选择标准本身相比具有附加益处。